The Swiss drugmaker raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions for drugs.
The company has beaten back an appeal by nearly 1,200 plaintiffs who claimed their cases were improperly dismissed by the federal judge overseeing mass torts litigation over its Zostavax shingles vaccine.
Muse is specifically built for healthcare companies operating in a highly regulated environment. It combines the agency’s celebrity and influencer expertise under one umbrella to develop high-impact engagements with the full range of health influencers.
The FDA on Tuesday rejected Orexo’s application for OX124, its high-dose naloxone nasal spray for the rescue treatment for opioid overdose.
After nixing a twice-daily version of its oral GLP-1 agonist, Pfizer is hoping to break into the weight-loss space with a once-daily version, but experts question its outlook.
4D Molecular Therapeutics revealed positive Phase II data Wednesday for its wet age-related macular degeneration candidate at the American Society of Retina Specialists (ASRS) annual scientific meeting.